دورية أكاديمية
The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC)
| العنوان: | The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC) |
|---|---|
| المؤلفون: | Naveed Z. Janjua, DrPH, Margot Kuo, MPH, Amanda Yu, MSc, Maria Alvarez, MSc, Stanley Wong, MSc, Darrel Cook, MSc, Jason Wong, MD, Jason Grebely, PhD, Zahid A. Butt, PhD, Hasina Samji, PhD, Alnoor Ramji, MD, Mark Tyndall, MD, Mel Krajden, MD |
| المصدر: | EBioMedicine, Vol 12, Iss C, Pp 189-195 (2016) |
| بيانات النشر: | Elsevier, 2016. |
| سنة النشر: | 2016 |
| المجموعة: | LCC:Medicine LCC:Medicine (General) |
| مصطلحات موضوعية: | Cascade of care, Hepatitis C, Linkage with care, Testing, Engagement with care, Prevalence, Treatment, Medicine, Medicine (General), R5-920 |
| الوصف: | Background: Population-level monitoring of hepatitis C virus (HCV) infected people across the cascade of care identifies gaps in access and engagement in care and treatment. We characterized a population-level cascade of care for HCV in British Columbia (BC), Canada and identified factors associated with leakage at each stage. Methods: The BC Hepatitis Testers Cohort (BC-HTC) includes 1.5 million individuals tested for HCV, HIV, reported cases of hepatitis B, and active tuberculosis in BC from 1990 to 2013 linked to medical visits, hospitalizations, cancers, prescription drugs and mortality data. We defined six HCV cascade of care stages: 1) estimated population prevalence; 2) HCV diagnosed; 3) HCV RNA tested; 4) genotyped; 5) initiated treatment; and 6) achieved sustained virologic response (SVR). Results: We estimated that 73,203 people were HCV antibody positive in BC in 2012 (undiagnosed: 18,301, 25%; diagnosed: 54,902, 75%). Of these, 56%(40,656) had HCV RNA testing; 34%(26,300) were genotyped; 12%( 8532 ) had received interferon-based therapy and 7%(5197) had SVR. Males, older birth cohorts, and HBV coinfected were less likely to undergo HCV RNA testing. Among those with chronic HCV infection, 32% had received liver-related care. Retention in liver care was more likely in those with HIV, cirrhosis, and drug/alcohol use and less likely in males and HBV coinfected. Conclusions: Although there are gaps in HCV RNA testing and genotyping after HCV diagnosis, the major gap in the cascade of care was low treatment initiation. People with comorbidities progressed through the cascade of testing and care but few received treatment. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2352-3964 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2352396416303905; https://doaj.org/toc/2352-3964 |
| DOI: | 10.1016/j.ebiom.2016.08.035 |
| URL الوصول: | https://doaj.org/article/3284c5354f9146709db73acf149fb979 |
| رقم الأكسشن: | edsdoj.3284c5354f9146709db73acf149fb979 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 23523964 |
|---|---|
| DOI: | 10.1016/j.ebiom.2016.08.035 |